Subsequently, using the AOM/DSS mouse model of CRC, we obtained a better understanding of the key role of ATP13A2 in tumour growth and confirmed the clinical therapeutic potential of ATP13A2.Future studies will investigate ATP13A2 as a metabolism‐targeting drug that might be a new treatment strategy for CRC. The gene discussed is ATP13A2; the disease is colorectal carcinoma.